Manna V K, Marks P, Gibson J R
Wellcome Research Laboratories, Beckenham, UK.
J Int Med Res. 1992 Apr;20(2):106-11. doi: 10.1177/030006059202000202.
In a double-blind, two-period crossover study, 24 healthy volunteers were evaluated to establish the time of onset of action of activity of acrivastine in suppressing the weal and flare response to intradermally injected histamine. Volunteers received single doses of 8 mg acrivastine and placebo according to a fully randomized, balanced treatment plan. Acrivastine significantly (P less than 0.002) reduced the flare response induced by 0.4 micrograms histamine challenge 15 min after oral acrivastine dosing when compared with placebo. A significant (P less than 0.001) reduction of the weal response was noted at 25 min, although trends in this direction were already present at earlier time points.
在一项双盲、两阶段交叉研究中，对24名健康志愿者进行评估，以确定阿伐斯汀抑制皮内注射组胺所致风团和潮红反应的起效时间。志愿者根据完全随机、均衡的治疗方案接受单剂量8毫克阿伐斯汀和安慰剂。与安慰剂相比，口服阿伐斯汀给药15分钟后，阿伐斯汀能显著（P<0.002）降低0.4微克组胺激发引起的潮红反应。在25分钟时观察到风团反应显著（P<0.001）降低，尽管在更早时间点就已出现这种趋势。
